266 related articles for article (PubMed ID: 34904808)
1. PARP Inhibition in Advanced Prostate Cancer.
Fenton SE; Chalmers ZR; Hussain M
Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
5. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
7. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
10. Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
Hofstad M; Huang EY; Woods A; Yin Y; Desai NB; Raj GV
Crit Rev Oncog; 2022; 27(1):81-96. PubMed ID: 35993980
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
Flippot R; Patrikidou A; Aldea M; Colomba E; Lavaud P; Albigès L; Naoun N; Blanchard P; Terlizzi M; Garcia C; Bernard-Tessier A; Fuerea A; Di Palma M; Escudier B; Loriot Y; Baciarello G; Fizazi K
Drugs; 2022 May; 82(7):719-733. PubMed ID: 35511402
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
13. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
15. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
16. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
17. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
18. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
Tsujino T; Takai T; Hinohara K; Gui F; Tsutsumi T; Bai X; Miao C; Feng C; Gui B; Sztupinszki Z; Simoneau A; Xie N; Fazli L; Dong X; Azuma H; Choudhury AD; Mouw KW; Szallasi Z; Zou L; Kibel AS; Jia L
Nat Commun; 2023 Jan; 14(1):252. PubMed ID: 36650183
[TBL] [Abstract][Full Text] [Related]
19. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
